iOmx Therapeutics AG

iOmx Therapeutics AG develops cancer therapeutics based on novel immune checkpoint targets, headquartered in Martinsried/Munich, Germany. The biopharmaceutical company is dedicated to transforming cancer treatment by leveraging next-generation immunotherapy approaches to enhance the body's ability to fight cancer. It has secured substantial venture capital, including a EUR 65 million Series B round in October 2021 and a EUR 40 million Series A, accumulating over EUR 100 million in total funding. Notable investors backing the company include Wellington Partners, Sofinnova Partners, M Ventures, MIG Capital AG, and Athos Service GmbH. Their lead program, IMT-07, was progressing towards clinical entry, planned for late 2022. iOmx Therapeutics AG was founded in 2016 by Elmar Maier, Nisit Khandelwal, Patrick Baeuerle, Philipp Beckhove, and Sebastian Meier-Ewert.

High-Level Overview

iOmx Therapeutics AG is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies that target immune evasion mechanisms in solid tumors, using its proprietary iOTargTM target screening platform to identify biomarker-enabled drug programs with single-agent activity.[1][2][4] Based in Martinsried near Munich, Germany, iOmx focuses on creating backbone therapies for prevalent solid tumor indications like clear cell renal cell carcinoma and angiosarcoma, serving patients with previously treated unresectable tumors through multimodal mechanisms that sensitize the immune system and arrest tumor cell cycles.[1][5] The company's lead candidate, OMX-0407 (a spectrum-selective SIK kinase inhibitor), is in Phase I/Ib trials with first efficacy data expected in 2025, while IOMX-0675 (a LILRB1/LILRB2 cross-specific antibody) received Clinical Trial Application approval in April 2025 and is set to enter clinics soon; earlier programs include IOMX-0235 for inflammatory bowel disease and discovery-stage bispecifics/T-cell engagers.[1][4][5] iOmx has raised over €120M from investors like Athos, Sofinnova Partners, Wellington Partners, MIG Capital, and M Ventures, fueling pipeline advancement.[1][3]

Origin Story

Founded in 2016 in Martinsried/Munich, iOmx Therapeutics traces its scientific roots to the German Cancer Research Center (DKFZ), leveraging deep insights into tumor and myeloid biology to pioneer immune checkpoint targets hijacked by cancer cells.[1][2] The company emerged from expertise in unexplored immune evasion pathways, building its proprietary iOTargTM platform for high-throughput target discovery, as highlighted in presentations like the 2023 AACR Annual Meeting.[3] Early traction came through venture backing exceeding €100M, including a €65M Series B round co-led by Athos and MIG Capital to advance programs like OMX-0407 (then IMT-07) into first-in-human trials and IMT-18 (now IOMX-0675).[1][3] Pivotal moments include regulatory approvals for clinical trials and a growing pipeline, reflecting a hands-on culture of curiosity, integrity, and collaboration in Munich's biotech hub.[2][4]

Core Differentiators

• Proprietary iOTargTM Platform: Enables high-throughput screening of myeloid and tumor biology to uncover novel immune checkpoints, translating immune evasion insights into biomarker-driven programs with single-agent potential across modalities like small molecules, antibodies, and bispecifics.[1][3][4]
• Multimodal Mechanisms: Programs like OMX-0407 combine immune sensitization, tumor microenvironment modulation, and direct cell cycle arrest for broad solid tumor activity; IOMX-0675 uniquely cross-targets LILRB1/LILRB2 to reverse suppression.[1][4][5]
• Pipeline Focus and Speed: Clinical-stage leads (OMX-0407 in Phase Ib, IOMX-0675 entering trials) plus preclinical assets like IOMX-0235 (Fc-enhanced anti-CCR9 for IBD) and discovery bispecifics/T-cell engagers, emphasizing first-in-class candidates for oncology and beyond.[4][5]
• Strong Funding and Ecosystem: Over €120M raised supports rapid progression; Munich location provides access to Europe's life science hub, fostering a culture of bold ideas and sustainability.[1][2][3]

Role in the Broader Tech Landscape

iOmx rides the wave of next-generation immuno-oncology, targeting myeloid-driven immune suppression in solid tumors where PD-1/PD-L1 therapies often fail, aligning with trends in biomarker-enabled, multimodal backbones for combination regimens.[1][3][4] Timing is ideal amid rising demand for novel checkpoints post-checkpoint inhibitor era, bolstered by market forces like advancing trial data (e.g., OMX-0407 efficacy in 2025) and regulatory nods in Europe.[1][4][5] By validating targets via iOTargTM—showcased at AACR—and expanding into bispecifics/T-cell engagers, iOmx influences the ecosystem by diversifying options for "cold" tumors and non-oncology like IBD, potentially reshaping standards in prevalent cancers.[3][5]

Quick Take & Future Outlook

iOmx is poised for inflection with 2025 milestones: OMX-0407 efficacy readouts, IOMX-0675 dosing, and preclinical advances into clinics, potentially validating its platform for partnerships or further funding.[1][4][5] Trends like AI-aided target discovery and bispecific proliferation will amplify its edge, while investor backing positions it to lead in myeloid immuno-oncology amid a push for single-agent efficacy in solid tumors.[1][3] Influence may evolve through backbone therapy adoption, expanding iOmx from Munich innovator to global pipeline shaper—transforming immune evasion biology into patient impact, as its clinical-stage momentum builds.[2][4]